RESUMO
OBJECTIVE: To investigate the distribution of the Life Essential 8 (LE8) score among adult patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and explore its association with disease activity. METHODS: A cross-sectional study was conducted to select adult patients with SLE and RA who were treated in the general department of the Second Hospital of Shanxi Medical University between May 2022 and September 2023. Through questionnaires, patients' diet, sleep, smoking habits, and daily exercise were evaluated. Additionally, blood glucose, blood lipids, inflammatory markers, and other relevant data were collected to assess the LE8 levels of the participants. The data was analyzed using SPSS 26.0. Both univariate and ordered multivariate logistic regression were employed to explore the distribution and influencing factors of the LE8 score among the patients. RESULTS: A total of 43 adult cases of SLE and 55 RA cases were studied, encompassing 11 males and 87 females with a mean age of 49.12 ± 15.86 years. The LE8 score averaged at 68.82 ± 12.29; specifically, the LE8 behavior score was 60.91 ± 17.78, and the LE8 factor score was 77.05 ± 14.30. The disease activity scores of both conditions showed a negative correlation with LE8. As DAS28 (r = - 0.96, P < 0.05) and SLEDAI (r = - 0.807, P < 0.05) scores increased, the LE8 score decreased. A low SLEDAI score serves as a protective factor for LE8 (OR (95% CI) = 0.07 (0.01, 0.37), P = 0.02). Furthermore, among patients with RA (OR (95% CI) = 0.03 (0.00, 0.22), P = 0.001) and SLE (OR (95% CI) = 0.06 (0.01, 0.35), P = 0.002), individuals boasting higher LE8 scores exhibit a reduced 10-year cardiovascular risk. CONCLUSIONS: Patients suffering from RA and SLE often exhibit low LE8 scores, reflecting a concerning cardiovascular health status-particularly in cases of high disease activity. Hence, it is imperative to prioritize the cardiovascular well-being of rheumatic patients. Key Points ⢠Research has revealed that individuals suffering from RA and SLE exhibit lower LE8 scores, potentially attributed to alterations in disease activity ⢠In this study, no statistically significant associations were discerned between inflammatory markers and LE8 scores among patients with RA and SLE. Nevertheless, among SLE patients specifically, a notable correlation was observed between ds-DNA levels and LE8 factor scores. ⢠Enhancing the compliance rate for the LE8 target among patients with RA and SLE could potentially mitigate the cardiovascular risk associated with these conditions.
RESUMO
[This corrects the article DOI: 10.3389/fcell.2021.765772.].
RESUMO
[This corrects the article DOI: 10.3389/fcell.2021.765772.].
RESUMO
Growing evidence has demonstrated that UBE2C plays a critical role in cancer progression, but there is no study focusing on the prognosis, upstream regulation mechanism, and immunological roles of UBE2C across diverse tumor types. In this study, we found that UBE2C was elevated in this human pan-cancer analysis, and high expression of UBE2C was correlated with poor prognosis. In addition, UBE2C expression was markedly associated with tumor mutation burden (TMB), microsatellite instability (MSI), immune cell infiltration, and diverse drug sensitivities. Finally, we showed that the METTL3/SNHG1/miRNA-140-3p axis could potentially regulate UBE2C expression. N(6)-Methyladenosine (m6A) modifications improved the stability of methylated SNHG1 transcripts by decreasing the rate of RNA degradation, which lead to upregulation of SNHG1 in non-small cell lung cancer (NSCLC). In vitro functional experiments showed that SNHG1, as a competing endogenous RNA, sponges miR-140-3p to increase UBE2C expression in NSCLC cell lines. Our study elucidates the clinical importance and regulatory mechanism of the METTL3/SNHG1/miRNA-140-3p/UBE2C axis in NSCLC and provides a prognostic indicator, as well as a promising therapeutic target for patients with NSCLC.
RESUMO
Lung cancer is the most common tumor with severe morbidity and high mortality. Increasing evidence has demonstrated that SNX20 plays crucial roles in the progression of human cancer. However, the functions and mechanism of SNX20 in LUAD are still barely known. Here, we employ the TCGA, GEO and CCLE databases to examine the expression of SNX20 in human varies cancer, the results shown that SNX20 is down-regulated in lung Adenocarcinoma, SNX20 level was significantly positive correlated with poor prognosis and lung cancer immune cell infiltration. We found that over-expression of SNX20 significantly restrain NSCLC cell proliferation and migration. Subsequently, we discover a network regulating SNX20 in LUAD, further study found that the decreased of the SNX20 likely caused by DNA hypermethylation. Furthermore, we identified that SNX20AR/miRNA-301a-3p mediated decreased of SNX20 correlated with lung cancer progression and cancer immune infiltration in LUAD. Our findings suggested that ncRNAs play a crucial role in the regulatory network of SNX20. Collectively, our findings demonstrate the suppressor roles of the SNX20AR/miRNA-301a-3p/SNX20 axis in Lung Adenocarcinoma, represent that SNX20 have the potential of as an effective therapeutic target in future.
RESUMO
In the tumor progression, transforming growth factor ß1 (TGFß1) plays a critical role in tumorigenesis as well as metastasis. It is known that high plasma level of TGFß1 in patients with advanced non-small cell lung cancer (NSCLC) is correlated with poor prognostics. In addition, the generation of cancer stem-like cells is associated with metastasis, drug resistance, and tumor recurrence, which also lead to poor outcomes in NSCLC patients. However, it remains unclear how TGFß1 promotes NSCLC cells to acquire stem-like properties and accelerate tumor metastasis. In our study, we found that short term TGFß1 treatment resulted in a significant epithelial-mesenchymal transition (EMT) morphological change in TGFß1-sensitive NSCLC cells but not in insensitive cells. Western blotting confirmed increased Vimentin and reduced E-Cadherin protein expression after TGFß1 treatment in A549, NCI-H1993, and NCI-H358 cells. TGFß1 incubation dramatically decreased in vitro cell proliferation and increased cell invasion in TGFß1-sensitive NSCLC cells but not in NCI-H1975, NCI-H1650, and HCC827 cells. Moreover, TGFß1 was able to enhance the mRNA expression of Oct4, Nanog and Sox2 and drastically increased anchorage-independent colony formation in TGFß1-sensitive NSCLC cells, suggesting the acquisition of cancer stem-like properties. Interestingly, we found that vascular endothelial growth factor receptor 3 (VEGFR3) mRNA expression was significantly elevated in TGFß1-sensitive NSCLC cells compared to insensitive cells. And TGFß1 was capable of inducing VEGF-C gene expression. Pharmacological blocking TGFß type I receptor kinase (ALK5) significantly inhibited TGFß1-induced VEGF-C expression. Silencing of ALK5 by siRNA also dramatically reduced TGFß1-induced VEGF-C expression in TGFß1-sensitive NSCLC cells. Therefore, TGFß1 contributes for NSCLC metastasis through promoting EMT, generation of high invasive cancer cells with stem-like properties, and increasing VEGF-C expression. Blocking TGFß pathway is a potential therapeutic target in human non-small cell lung cancer.